2 September 2015 — Ken Boal, President of The Business/Higher Education Round Table is very pleased to announce the appointment of Dr. Russell J Howard, BSc (Hons), PhD as the inaugural BHERT Fellow.
The appointment of Dr. Howard as the inaugural BHERT Fellow is an acknowledgement of the importance of the work that BHERT undertakes. Now in its 25th year of operation, BHERT is the only national organization that works across the sectors of business, industry, higher education and government.
At such an auspicious time in its history, Mr. Boal believes the appointment of such a successful and eminent Australian can only be a positive in raising the profile of the good work delivered by BHERT.
The role of the BHERT Fellow is primarily to raise awareness on issues related to collaboration between the higher education sector, business and industry. The BHERT Fellow will bring a renewed focus to what BHERT stands for and the value of BHERT initiatives that promote collaboration.
Russell Howard is an Australian-born entrepreneur and scientist who dedicated his career to life sciences to generate novel products.
After his PhD at Melbourne University and postdoctoral studies at the Walter and Eliza Hall Institute, he worked many years in the US. He worked at the NIH, MD, as a tenured scientist on the molecular basis for human cerebral malaria pathology. This work generated a malaria diagnostic product used internationally for many years.
On the West coast he continued his malaria research while working at biotechnology companies (DNAX-Schering Plough & Affymax) on immunology and small molecule combinatorial chemistry respectively. He was CEO of Maxygen (spun out of Affymax/Glaxo-Wellcome) which he took public on NASDAQ and grew into multiple businesses using recombinatorial "DNA shuffling" to create novel products in chemicals manufacture, agriculture and protein drugs.
After Maxygen he founded a clean technology company, Oakbio, that converts waste CO2 that would otherwise contribute to increased global warming into valuable chemical products.
Back in Australia since 2012, he works for two local enterprises and serves as non-executive Director for two listed Australian companies.
He is Executive Chairman at NeuClone, developing a multi-product portfolio of biosimilar monoclonal antibody drugs differentiated by low production cost.
Russell is also working at the Kinghorn Centre for Clinical Genomics, also in Sydney. As Head of Commercial Strategy for the genomics business he is working to commercialize novel genomics products, including clinical pathology reports based on whole genome sequencing.
His passion is to see the wealth of innovation in the Australian Life Sciences bear fruit in breakthrough global products, with value derived from Australia captured locally to feed a virtuous cycle of expanded Life Sciences innovation and commercialization.
Driving collaboration across business, industry and tertiary education.
Copyright © 2001-
Business/Higher Education Round Table (BHERT). All right reserved. ABN 80 050 207 942.
Website by Hope Stewart—Website Design & Management